regression model to investigate critical features associated with prognosis.

**Results** Patients with low MA (called intramuscular fat [IMF] deposition) had shorter median survival than non-IMF deposition (73 11.61 vs. 252 26.56 days, p=0.008) as also observed shorter in patients with alpha-fetoprotein (AFP) level ≥200 ng/ml than AFP <200 ng/ml (69 31.31 vs. 92 86.03 days, p=0.015) as depicted in IDDF2018-ABS-0195 Figure 1. By univariate analysis, IMF deposition (p=0.012), HBV DNA level (p=0.048), Child-Pugh (CP) class B (p=0.019), CP class C (p=0.009), BCLC stage C (p=0.009), BCLC stage D (p<0.001) and AFP (p=0.018) were significantly associated with mortality. However, multivariate analysis revealed that only IMF deposition (HR, 2.390; 95% CI, 1.007–68.253; p=0.009), BCLC stage C (HR, 4.641; 95% CI, 1.369–15.732; p=0.014) and BCLC stage D (HR, 14.681; 95% CI, 3.158–68.253; p=0.001) were independently associated with mortality.

**Conclusions** Muscle Attenuation and BCLC stage were significant independent predictors of survival in HCC Indonesian patients. External validation of these prognostic factors in larger cohorts of HCC patients is warranted.

**IDDF2018-ABS-0200** NON-LINEAR ASSOCIATION BETWEEN SERUM HEPATITIS B VIRUS DNA LEVELS AND HEPATOCELLULAR CARCINOMA RISK IN TREATMENT-NAIVE, NON-CIRRHOTIC CHRONIC HEPATITIS B PATIENTS

1Gi-Ae Kim*, 2Seungbong Han, 3Gwanghyn Choi, 4Jeeoung Choi, 5Young-Suk Lim, 1Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Korea, South; 2Department of Applied Statistics, Gachon University, Korea, South; 3Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Korea, South.

10.1136/gutjnl-2018-IDDFabstracts.232

**Background** The REVEAL-HBV studies on the natural history of chronic hepatitis B (CHB) showed a linear correlation between serum HBV DNA levels and the risk of hepatocellular carcinoma (HCC). However, virus titers above 10^6 copies/mL were not quantified, and most of the patients were HBeAg-negative (85%). The progression of these HBeAg-negative patients would not be identical to that of young HBeAg-positive immune-tolerant phase patients.

**Methods** The study subjects were recruited from a historical cohort of 4367 treatment-naive, non-cirrhotic CHB patients (1240 HBeAg-positive and 3127 HBeAg-negative) with serum ALT levels lower than 2 x upper limit of normal (females, <19 IU/mL; males, <30 IU/mL) at a tertiary referral hospital in Korea. Cox proportional hazards regression model predicted HCC risk considering sex, age, HBeAg status, HBV DNA levels, ALT levels, and platelet counts.

**Results** During the total follow-up of 23 690 person-years, 221 patients (5.1%) developed HCC. Old age, male gender, and lower platelet counts were found to be associated with an increased risk of HCC. Among HBeAg-negative patients, HBV DNA levels were linearly associated with increased risk of HCC. In contrast, among HBeAg-positive patients, HBV DNA levels were inversely associated with the risk of HCC. The risk of HCC was the lowest in HBeAg negative patients with HBV DNA level below 4 log_{10}IU/mL (reference group) and was the highest in HBeAg positive patients with HBV DNA levels between 4 log_{10}IU/mL and 6 log_{10}IU/mL (HR 6.89; 95% CI 4.20–11.29). HBeAg-positive patients with HBV DNA levels above 8 log_{10}IU/mL showed the similar risk of HCC compared with the reference group (HR 1.36; 95% CI 0.65–2.84).

**Conclusions** In our cohort, the association between HBV DNA levels and HCC risk was not linear but was parabolic. HCC risk was the highest in patients with HBV DNA levels between 4 log_{10}IU/mL and 6 log_{10}IU/mL. These data may help assess the HCC risk among the patients who are not subject to antiviral treatment which consequently calls attention to the necessity of developing a new treatment indication.

**IDDF2018-ABS-0201** FAECAL MICROBIOTA TRANSPLANTATION INDUCED HBSAG DECLINE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS AFTER LONG-TERM ANTIVIRAL THERAPY

1Yuruo Xie*, 2Zhangran Chen, 3Fei Zhou, 4Liqiang Chen, 5Jianquan He, 6Chuanxing Xiao, 1Hongchi Xu, 7Jianlin Ren, 8Xiang Zhang, 9Zhongshan Hospital Department of Gastroenterology, Xiamen University, Xiamen, China; 10Institute for Microbial Ecology, Medical College of Xiamen University, Xiamen, China

10.1136/gutjnl-2018-IDDFabstracts.233

**Background** Serum HBsAg decline is an index for the effectiveness of antiviral treatment hepatitis B virus (HBV) e-antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. Unfortunately, for entecavir (ETV), HBsAg decline or clearance only occurs in a minority of patients even after decades of antiviral therapy. Our previous study showed that Faecal microbiota transplantation (FMT) was able to induce HBeAg clearance in patients with positive HBeAg after long-term antiviral therapy. However, the effect of FMT on HBeAg negative CHB patients after long-term antiviral therapy is still unclear. Thus, we reported a case-controlled, open-label pilot trial of FMT for HBeAg negative CHB patients.

**Methods** We recruited 10 patients who remained HBsAg positive following >1 years of ongoing ETV antiviral therapy. 5 of them were enrolled in the FMT arm while other 5 were enrolled in the control arm. All patients went on their previous antiviral therapy. We performed FMT via nasojejunal tube for the FMT arm every 2 weeks. The faecal microbial community was analysed using Illumina Hisequencing of 16S rDNA and bioinformatics methods. Serum HBsAg and endotoxin levels were monitored every 2 weeks.

**Results** Serum HBsAg declined gradually after each time of FMT in the FMT arm compared to control arm. FMT induced serum HBsAg decline up to 55.27%±8.52% in the trial group accompanied with serum endotoxin decline while serum HBsAg in the control group increased 38.07% which may closely be related to drug resistance. 16S rDNA analysis of the stools showed that gut microbiota in the FMT group transformed towards the donors. In particular, the proportion of Bifidobacterium, Streptococcus, Clostridium, Clostridiaceae, Butylibacter, Coprocosoccus and Megamonas in the gut microbiota of the FMT group decreased significantly towards the donors while the proportion of Bacteroides, Butyricimonas, Odoribacter, Prevotella, Parabacteroides, Anaerostipes, Oscillibacter, Ruminococcaceae and Sutterella increased towards the donors.

**Conclusions** This study suggested that HBsAg decline in the serum of HBeAg negative CHB patients were detected after several times of FMT accompanied with serum endotoxin decline.